Zhi-Fuzi, a cardiotonic Chinese herb, a new medical treatment choice for portal hypertension?

Experimental Biology and Medicine

Volumn 232, Issue 4, 2007, Pages 557-564

  Lin, Jui Shan ^a   Chan, Cho Yu ^b   Yang, Chi ^c   Wang, Yao Horng ^d   Chiou, Hue Ying ^e   Su, Yi Chang ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d JEN TEH JUNIOR COLLEGE OF MEDICINE   (Taiwan)

^e ANIMAL TECHNOLOGY INSTITUTE TAIWAN   (Taiwan)

Author keywords

Chinese medicine; Portal hypertension; Portal vein ligation; Zhi Fuzi (Radix Aconiti lateralis preparata)

Indexed keywords

CARDIOTONIC AGENT; HERBACEOUS AGENT; PLANT EXTRACT; PROPRANOLOL; UNCLASSIFIED DRUG; ZHI FUZI EXTRACT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHINESE HERB; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; HEMODYNAMICS; LOW DRUG DOSE; MALE; NONHUMAN; PORTAL HYPERTENSION; RAT; ZHI FUZI;

ACONITUM; ANIMALS; BLOOD PRESSURE; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUGS, CHINESE HERBAL; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; MEDICINE, CHINESE TRADITIONAL; PROPRANOLOL; RATS; RATS, SPRAGUE-DAWLEY; VASODILATOR AGENTS;

RATTUS;

EID: 34047134659     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bosch J, Navasa M, García-Pagán JC, DeLacy AM, Rodes J. Portal hypertension. Med Clin North Am 73:931-953, 1989.
2. D'Amico G, De Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 38:599-612, 2003.
3. D'Amico G, Luca A. Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. Baillieres Clin Gastroenterol 11:243-256, 1997.
4. Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med 305:1371-1374; 1981.
5. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites and spontaneous bacterial peritonitis. Gastroenterology 120:726-748, 2001.
6. Kroeger RJ, Groszmann RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model. Hepatology 5:97-101, 1985.
7. Vorobioff J, Picabea E, Villavicencio R, Puccini V, Rossi O, Bordato J, Audano M. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 7:648-653, 1987.
8. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 19:475-505, 1999.
9. Lebrec D. Prevention of first variceal bleeding: drugs. In: Groszmann RJ, Bosch J, Eds. Portal Hypertension in the 21st Century. Boston: Kluwer Academic Publishers, pp221-226, 2004.
10. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Gao H, Makuch R; Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 353:2254-2261, 2005.
11. Chen SY, Li F. Formulae that regulate blood. In: A Clinical Guide to Chinese Herbs and Formulae. New York: Churchill Livingstone, pp148-151, 1993.
12. Xu XC. Prescription for treating blood disorder. In: Pharmacology of Traditional Chinese Medical Formulae. Beijing: Higher Education Press, pp324-326, 1994.
13. Huang TK. Fuzi. In: A Handbook of the Composition and Pharmacology of Common Chinese Drugs. Beijing: Chinese Medicine Technology Press, pp921-928, 1994.
14. Chang HM. Zhi-Fuzi and Chuanwu. In: Pharmacology and Applications of Chinese Materia Medica. (Vol I) Philadelphia: World Scientific Publishing Co Pte Ltd, pp668-673, 1986.
15. Chojkier M, Groszmann RJ. Measurement of portal systemic shunting in the rat by using gamma-labeled microspheres. Am J Physiol 240:G371-G375, 1981.
16. Hillon P, Blanchet L, Lebrec D. Effect of propranolol on hepatic blood flow in normal and portal hypertensive rats. Clin Sci 63:29-32, 1982.
17. Albillos A, Colombato LA, Groszmann RJ. Vasodilatation and sodium retention in prehepatic portal hypertension. Gastroenterology 102:931-935, 1992.
18. Bosch J, Groszmann RJ. Portal Hypertension. Pathophysiology and treatment. Oxford: Blackwell Scientific Publications, pp72-92, 1994.
19. Chen HC, Hsieh MT, Chang SS, Liu SL. Long-term reno-cardiovascular effects of orally administered aconiti tuber in humans. Am J Chin Med 18:25-33, 1990.
20. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 19:475-505, 1999.
21. Lin HC, Soubrane O, Cailmail S, Lebrec D. Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats. J Hepatol 13:213-219, 1991.
22. Bosch J, Pizcueta P, Feu F, Fernandez M, García-Pagán JC. Pathophysiology of portal hypertension. Gastroenterol Clin North Am 21:1-14, 1992.